Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Mount Sinai Health System, New York

Columbia University, New York

Memorial Sloan Kettering Cancer Center, New York

University of Pennsylvania, Abramson Cancer Center, Philadelphia

Emory University, Atlanta

Vanderbilt University, Nashville

Ohio State University, Columbus

Mayo Clinical, Rochester

Northwestern, Chicago

The University of Kansas Cancer Center, Westwood

City of Hope, Duarte

Massachusetts General Hospital, Boston